| Literature DB >> 28109187 |
Md Fakruddin1, Md Nur Hossain2, Monzur Morshed Ahmed2.
Abstract
BACKGROUND: Probiotic yeast has become a field of interest to scientists in recent years.Entities:
Keywords: Activity; Anti-bacterial; Anti-oxidant; Immuno; Probiotic; Saccharomyces
Mesh:
Substances:
Year: 2017 PMID: 28109187 PMCID: PMC5251302 DOI: 10.1186/s12906-017-1591-9
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1Stress tolerance of the S. cerevisiae IFST062013 isolate
Different probiotic properties of the yeast isolate
| Property |
| |
|---|---|---|
| Cholesterol assimilation | 33% | |
| Enzyme activity assay | amylase | 84 unit/g cell |
| protease | 1760 unit/g cell | |
| lipase | 77 unit/g cell | |
| cellulase | 39 unit/g cell | |
|
| + | |
| total Glutathione production | 1.48 mg/100 ml yeast | |
| Galactosidase enzyme production | - | |
| Production of siderophore | + | |
| Biofilm formation | Strong (SBF > 1) | |
| Auto-aggregation ability | 61.34% | |
Antibacterial activity of the yeast isolate
| Test organism | Source ID (ATCC) | Zone diameter (mm) | ||||
|---|---|---|---|---|---|---|
| Yeast isolate | Doxycycline | |||||
| Whole cell | Culture supernatant | Cell lysate | ||||
| Gram positive |
| 11774 | 7 | 5.1 | 11.6 | 21 |
|
| 25923 | 7.5 | 4.9 | 10.3 | 24 | |
|
| 10876 | 7 | 6.1 | 9.4 | 12 | |
|
| 842 | 8.5 | 5.9 | 11.4 | 21 | |
|
| 13578 | 7 | 5.4 | 9.8 | 28 | |
|
| 29212 | 6.5 | 5.3 | 10.4 | 19 | |
| Gram negative |
| 65154 | 11.5 | 8.3 | 14.8 | 27 |
|
| 12022 | 12.0 | 7.9 | 15.2 | 15 | |
|
| 13883 | 10.5 | 7.5 | 13.7 | 22 | |
|
| 13315 | 10 | 8.1 | 15.1 | 17 | |
|
| 25922 | 11 | 8.7 | 14.9 | 19 | |
|
| 15748 | 13.5 | 9.6 | 16.3 | 26 | |
|
| 27853 | 12.5 | 9.1 | 16.1 | 21 | |
In-vitro antifungal activity of CHET and fluconazole
| Organism | Source ID (DSM) | Zone diameter (mm) | |||
|---|---|---|---|---|---|
| Yeast | Fluconazole | ||||
| Whole cell | Culture supernatant | Cell lysate | |||
|
| 63535 | 16.5 | 14.6 | 19.5 | 45 |
|
| 737 | 27.2 | 24.3 | 33.4 | 65 |
|
| 824 | 21.6 | 18.4 | 24.1 | 41 |
|
| 1075 | 23.5 | 19.7 | 25.3 | 48 |
|
| 2200 | 19.7 | 17.5 | 22.7 | 46 |
Fig. 2Pharmacological activity of the S. cerevisiae IFST062013 isolate
Ferrous iron chelation of yeast isolate and EDTA
| SL | Sample concentration (mg/ml) | % Fe Chelation | |
|---|---|---|---|
| Standard EDTA | Yeast isolate | ||
| 1 | 2.5 | 47.86 ± 1.11 | 13.84 ± 0.97 |
| 2 | 3.5 | 63.24 ± 0.93 | 19.54 ± 1.15 |
| 3 | 4.5 | 76.15 ± 1.42 | 23.42 ± 0.68 |
| 4 | 5.5 | 86.34 ± 1.69 | 28.33 ± 1.43 |
| 5 | 6.5 | 91.25 ± 0.75 | 33.77 ± 1.85 |
Values are expressed as mean ± SD of three parallel measurements
Fig. 3Safety evaluation of S. cerevisiae IFST 062013 in mice. a comparison of body weight; b comparison of AST, ALP, ALT and cholesterol level; c Enterobacteria and S. cerevisiae count in the feces; d comparison of liver weight and spleen weight ratio of treated and control mice
Fig. 4Immuno-modulatory activity of the S. cerevisiae IFST062013. a T-lymphocyte proliferation; b IFN-α, c IFN-γ, d IL-10 production in serum of treated and control mice; e Gene expression of cytokines (TLR-2, IFN-γ, IL-4, Foxp3 and TGF-β) in intestinal mucosa